0
Skip to Content
Roivant Social Ventures
About Us
Our Story
Our Core Commitments
Our Team
Our Work
Our Approach
Our Focus Areas
Our Partners
Our Global Access Scorecard
Corporate Partnerships
RSV In The Spotlight
News
Publications
Events & Recordings
Roivant Social Ventures
About Us
Our Story
Our Core Commitments
Our Team
Our Work
Our Approach
Our Focus Areas
Our Partners
Our Global Access Scorecard
Corporate Partnerships
RSV In The Spotlight
News
Publications
Events & Recordings
Folder: About Us
Back
Our Story
Our Core Commitments
Our Team
Folder: Our Work
Back
Our Approach
Our Focus Areas
Our Partners
Our Global Access Scorecard
Corporate Partnerships
Folder: RSV In The Spotlight
Back
News
Publications
Events & Recordings
Fortune feature on RSV’s Philanthropy Model, “Corporate America’s philanthropy model doesn’t work. It’s time for a better one.” by Lindsay Androski, RSV CEO
Publications Danny Tetzl 2/15/22 Publications Danny Tetzl 2/15/22

Fortune feature on RSV’s Philanthropy Model, “Corporate America’s philanthropy model doesn’t work. It’s time for a better one.” by Lindsay Androski, RSV CEO

Corporate America is exceedingly generous. With nearly $17 billion in donations in 2020 alone, businesses are working hard to address everything from equity to education to addiction.

Read More
Towards access for all: 1st Working Group Report for the Global Gene Therapy Initiative (GGTI)” published in Nature
Publications Danny Tetzl 9/29/21 Publications Danny Tetzl 9/29/21

Towards access for all: 1st Working Group Report for the Global Gene Therapy Initiative (GGTI)” published in Nature

The gene and cell therapy field saw its first approved treatments in Europe in 2012 and the United States in 2017 and is projected to be at least a $10B USD industry by 2025.

Read More

RSV In the Spotlight

About Us

Our Work 

Newsletter

Thank you!

Copyright © 2022 Roivant Social Ventures. All rights reserved. Privacy Policy | Terms & Conditions | EIN: 83-3947490
151 West 42nd Street | 15th Floor New York, NY 10036